| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 0 | 2 | 3 | 34 | 48 | 34 | 54 | 61 | 53 | 51 | 44 | 28 |
| Expenses | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 42 |
| EBITDA | -5 | -11 | -8 | -7 | -10 | -18 | -17 | -33 | -15 | -8 | -14 | -15 |
| Operating Profit % | 0 % | -962 % | -246 % | -22 % | -21 % | -56 % | -33 % | -57 % | -30 % | -17 % | -35 % | -59 % |
| Depreciation | 2 | 5 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 7 |
| Interest | 4 | 1 | 4 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 |
| Profit Before Tax | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| EPS in ₹ | -8.24 | -12.49 | -11.68 | -12.97 | -12.83 | -17.90 | -14.37 | -20.81 | -11.30 | -9.15 | -12.49 | -12.70 |
Krebs Biochemicals & Industries
Krebs Biochemicals & Industries
66.37
-0.75
(-1.12%)
Key Fundamentals
Market Cap
143.10 Cr
EPS
-12.49
PE Ratio
-5.27
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
129.07
52 Week Low
64.16
PB Ratio
-0.92
Debt to Equity
0.00
Sector
Pharmaceuticals Actual
Company News
View All News
Krebs Biochemicals Industries Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported a loss before tax of Rs 1,146.73 lacs for the half-year period, compared to a loss of Rs 2,093.20 lacs in the corresponding period last year. Revenue from operations stood at Rs 1,977.70 lacs for the half-year. The company's cash and cash equivalents decreased to Rs 12.71 lacs as of September 30, 2025, from Rs 14.16 lacs at the beginning of the year. Net cash flow from operating activities was negative at Rs 167.56 lacs. The Board of Directors approved these results in a meeting held on November 4, 2025. The company operates in a single business segment and has no subsidiaries, associates, or joint venture companies.
Krebs Biochemicals Shareholders Approve All Nine Resolutions at 33rd AGMSep 27, 2025
Krebs Biochemicals & Industries Limited held its 33rd Annual General Meeting on September 26, 2025, where all nine resolutions were passed by the required majority. Key approvals included adoption of audited financial statements for the year ended March 31, 2025, re-appointment of directors Mr. Avinash Ravi and Mr. Pabitrakumar K Bhattacharyya who retired by rotation, and appointment of statutory auditors. Shareholders also approved the appointment of Mr. Manish Kumar Jain as Director and subsequently as Managing Director and CEO. Other resolutions covered related party transactions with Ipca Laboratories Limited, ratification of cost auditors' remuneration, and appointment of DSMR & Associates as secretarial auditors for five years starting from financial year 2025-26. The company has 9,111 shareholders on record date, with 31 shareholders attending the meeting either in person or through proxy.
Krebs Biochemicals and Industries Limited published its unaudited financial results for the quarter ended June 30, 2025. The company reported total income from operations of Rs 549.26 lakhs, down from Rs 643.85 lakhs in the previous quarter and Rs 1,292.25 lakhs in the same quarter last year. The company posted a net loss of Rs 532.43 lakhs for the quarter, compared to a loss of Rs 825.31 lakhs in the previous quarter and Rs 517.11 lakhs in the corresponding quarter of the previous year. Total comprehensive income showed a loss of Rs 532.43 lakhs. The company's equity share capital remained unchanged at Rs 2,156.06 lakhs. Basic and diluted earnings per share were negative at Rs 2.47 per share of Rs 10 each. The board approved these results on August 7, 2025, and they were published in newspapers on August 8, 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,784.10 | #1 4,28,065.35 | 40.27 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 74.53 | |
6,454.00 | 1,71,333.42 | 69.17 | 9,712.00 | 18.67 | 2,191 | 35.10 | 46.81 | |
3,731.40 | 1,26,287.53 | 59.99 | 11,539.40 | 6.99 | 1,911 | 30.46 | 56.17 | |
1,526.80 | 1,23,327.89 | 22.52 | 28,409.50 | 7.12 | 5,291 | 3.71 | 47.29 | |
1,250.20 | 1,04,343.41 | #1 18.09 | 33,741.20 | 16.73 | 5,725 | -0.38 | 54.25 | |
930.20 | 93,599.89 | 18.57 | 23,511.00 | 18.55 | 4,615 | 34.60 | 33.90 | |
2,025.40 | 92,511.06 | 21.51 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 57.78 | |
2,223.10 | 91,760.34 | 51.75 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 29.21 | |
1,235.80 | 71,775.46 | 21.23 | 32,345.60 | 9.43 | 3,484 | 3.81 | 74.03 | |
5,724.00 | 68,439.01 | 28.33 | 13,458.30 | 3.70 | 2,216 | 10.98 | 64.07 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-13.56 %
Net Income Growth
36.55 %
Cash Flow Change
-434.32 %
ROE
11.30 %
ROCE
148.03 %
EBITDA Margin (Avg.)
100.06 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
| Fixed Assets | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 |
| Current Assets | 15 | 9 | 13 | 17 | 31 | 19 | 21 | 36 | 16 | 17 | 10 |
| Capital Work in Progress | 0 | 11 | 4 | 4 | 4 | 4 | 12 | 8 | 4 | 2 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 |
| Total Liabilities | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 |
| Current Liabilities | 29 | 30 | 32 | 42 | 55 | 43 | 48 | 78 | 49 | 62 | 104 |
| Non Current Liabilities | 61 | 74 | 89 | 101 | 102 | 116 | 154 | 187 | 225 | 236 | 212 |
| Total Equity | 18 | 13 | 2 | -18 | -14 | -25 | -43 | -75 | -100 | -119 | -146 |
| Reserve & Surplus | -14 | -4 | -12 | -32 | -31 | -43 | -67 | -97 | -121 | -141 | -168 |
| Share Capital | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 6 | -6 | -0 | 0 | 17 | -17 | 1 | -1 | 0 | 0 | 0 |
| Investing Activities | -3 | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 | -5 |
| Operating Activities | -45 | -15 | -11 | -6 | 4 | -36 | -15 | -17 | -25 | 2 | -8 |
| Financing Activities | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 |
Share Holding
| % Holding | Mar 2021 | Apr 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 70.05 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % | 72.74 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % | 0.01 % | 0.50 % | 0.50 % | 0.50 % | 0.50 % | 0.50 % | 0.50 % | 0.50 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 19.03 % | 17.32 % | 18.26 % | 19.34 % | 18.96 % | 19.24 % | 19.26 % | 18.77 % | 18.67 % | 18.57 % | 18.54 % | 18.80 % | 19.00 % | 20.11 % | 19.97 % | 19.80 % | 20.02 % | 20.42 % | 19.73 % | 19.70 % |
| Others | 10.92 % | 9.94 % | 9.00 % | 7.91 % | 8.30 % | 8.01 % | 8.00 % | 8.48 % | 8.59 % | 8.68 % | 8.71 % | 8.45 % | 8.25 % | 6.65 % | 6.79 % | 6.96 % | 6.74 % | 6.34 % | 7.03 % | 7.06 % |
| No of Share Holders | 0 | 6,400 | 6,400 | 7,096 | 8,571 | 8,166 | 9,531 | 9,533 | 9,650 | 9,294 | 9,393 | 9,030 | 8,990 | 8,909 | 8,848 | 9,425 | 9,091 | 8,798 | 9,118 | 8,912 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 01 Feb 2019 |  Rights | 21:100 | 31 Jan 2019 | 110.30 | 97.70 |
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 82.67 | 82.25 |
| 11 Nov 2024 |  Quarterly Result Announcement | NA | 11 Nov 2024 | 77.10 | 92.51 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 90.26 | 97.00 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 73.00 | 77.72 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 82.49 | 79.86 |
| 26 Sept 2025 | Annual General Meeting | NA | 26 Sept 2025 | 73.50 | 74.14 |
| 04 Nov 2025 | Quarterly Result Announcement | NA | 04 Nov 2025 | 71.15 | 69.20 |
Announcements
Report On Re-Lodgement Of Transfer Requests Of Physical Shares Oct 2025
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationNov 05, 2025
Nov 05, 2025Result Sept 2025Nov 04, 2025
Nov 04, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 04, 2025
Nov 04, 2025Board Meeting Intimation for Board Meeting Intimation For The Quarter Ended 30.09.2025.Oct 16, 2025
Oct 16, 2025Report On Re-Lodgement Of Transfer Requests Of Physical SharesOct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 27, 2025
Sep 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Sep 26, 2025Closure of Trading WindowSep 23, 2025
Sep 23, 2025Report On Re-Lodgement Of Transfer Requests Of Physical SharesSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2025
Aug 29, 2025Notice Of 33Rd Annual General Meeting Of The CompanyAug 28, 2025
Aug 28, 2025Reg. 34 (1) Annual Report.Aug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Board Comments On Fine Levied By ExchangesAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 07, 2025
Aug 07, 2025ResultAug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 25, 2025
Jul 25, 2025Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 7Th August 2025Jul 22, 2025
Jul 22, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 23, 2025
Jun 23, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Result For The Year Ended 31.03.2025May 20, 2025
May 20, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 20Th May 2025May 20, 2025
May 20, 2025Board Meeting Intimation for To Consider And Approved Audited Financial Results For 4Th Quarter And Year Ended 31.03.2025May 07, 2025
May 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 02, 2025
Apr 02, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Mar 31, 2025Announcement under Regulation 30 (LODR)-CessationMar 24, 2025
Mar 24, 2025Closure of Trading WindowMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-CessationMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 26, 2025
Feb 26, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 24, 2025
Feb 24, 2025Announcement under Regulation 30 (LODR)-CessationFeb 11, 2025
Feb 11, 2025Order Received From Andhra Pradesh Pollution Control BoardFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 05, 2025
Feb 05, 2025Reconstitution Of Various Committees Of The Board Of CompanyFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 04, 2025
Feb 04, 2025Integrated Filing (Financial)Feb 04, 2025
Feb 04, 2025Financial Result For The Quarter Ended 31.12.2024Feb 04, 2025
Feb 04, 2025Board Meeting Outcome for Outcome Of Board MeetingFeb 04, 2025
Feb 04, 2025Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 15, 2025
Jan 15, 2025Integrated Filing (Governance)Jan 13, 2025
Jan 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 02, 2025
Jan 02, 2025Announcement under Regulation 30 (LODR)-CessationDec 31, 2024
Dec 31, 2024Reply To Clarification Sought On Price MovementNov 28, 2024
Nov 28, 2024Clarification sought from Krebs Biochemicals & Industries LtdNov 28, 2024
Nov 28, 2024Technical Indicators
RSI(14)
Neutral 37.26
ATR(14)
Less Volatile 2.84
STOCH(9,6)
Neutral 43.82
STOCH RSI(14)
Oversold 17.21
MACD(12,26)
Bearish -0.05
ADX(14)
Weak Trend 14.63
UO(9)
Bearish 40.98
ROC(12)
Downtrend And Accelerating -3.87
WillR(14)
Neutral -75.00
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
